Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 421B 4.43B 3.97B 3.65B 3.31B 6.19B 6.31B 43.47B 17.51B 221B 16.63B 16.27B 698B P/E 2027 *
36.1x
P/E 2028 * 31.4x
Enterprise Value 421B 4.43B 3.97B 3.65B 3.31B 6.19B 6.31B 43.47B 17.51B 221B 16.63B 16.27B 698B EV / Sales 2027 *
9.88x
EV / Sales 2028 * 8.91x
Free-Float
24.37%
Yield 2027 *
1.19%
Yield 2028 * 1.19%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day-1.28%
1 week+3.27%
1 month-10.26%
3 months-6.40%
6 months+6.33%
Current year+0.51%
1 week 2,387.55
Extreme 2387.55
2,540
1 month 2,342.7
Extreme 2342.7
2,785.3
Current year 2,088
Extreme 2088
3,121.1
1 year 2,088
Extreme 2088
3,121.1
3 years 1,387.9
Extreme 1387.9
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-11-30
Director of Finance/CFO - 2026-03-31
Chief Operating Officer - 2024-12-31
Director TitleAgeSince
Chairman 73 2019-03-31
Director/Board Member 59 2020-05-17
Director/Board Member 67 2022-05-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+3.27%-5.36%+74.51% 4.43B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.75%+5.64%+41.39%+83.56% 426.64B
Weighted average by Cap. +2.00%+6.59%+50.45%+100.41%

Financials

2027 *2028 *
Net sales 42.57B 448M 402M 370M 335M 626M 639M 4.4B 1.77B 22.39B 1.68B 1.65B 70.64B 47.24B 498M 446M 410M 372M 695M 709M 4.88B 1.97B 24.85B 1.87B 1.83B 78.39B
Net income 11.65B 123M 110M 101M 91.7M 171M 175M 1.2B 485M 6.13B 461M 451M 19.34B 13.42B 141M 127M 117M 106M 197M 201M 1.39B 558M 7.06B 530M 519M 22.27B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pharmaceuticals Limited
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26-10-30 ₹2,483.55 -1.28% 1,795
26-10-29 ₹2,515.65 +0.76% 2,210
26-10-28 ₹2,496.65 +0.32% 1,048
26-10-27 ₹2,488.75 +1.66% 4,368
26-10-26 ₹2,448.15 +1.80% 2,133
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,483.55INR
Average target price
3,097.25INR
Spread / Average Target
+24.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GlaxoSmithKline Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock